PDCD1 and colorectal carcinoma: To address this, we accessed single cell profiles of tumoral CD8+ T cells from a recently published scRNAseq dataset of 19 MSI CRC patients (GSE205506)104 (Fig. 7c), that were either untreated, treated with anti-PD-1 ICB or a combination of anti-PD-1 ICB and celecoxib (NCT03926338) (Fig. 7d).